Akari Therapeutics (AKTX) Competitors $1.20 +0.01 (+0.42%) As of 01/17/2025 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends AKTX vs. BDTX, TIL, XBIT, ALGS, TNYA, LPTX, ATOS, ANRO, IVA, and NVCTShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Black Diamond Therapeutics (BDTX), Instil Bio (TIL), XBiotech (XBIT), Aligos Therapeutics (ALGS), Tenaya Therapeutics (TNYA), Leap Therapeutics (LPTX), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Black Diamond Therapeutics Instil Bio XBiotech Aligos Therapeutics Tenaya Therapeutics Leap Therapeutics Atossa Therapeutics Alto Neuroscience Inventiva Nuvectis Pharma Akari Therapeutics (NASDAQ:AKTX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings. Is AKTX or BDTX more profitable? Akari Therapeutics' return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Black Diamond Therapeutics N/A -68.08%-49.65% Does the MarketBeat Community favor AKTX or BDTX? Akari Therapeutics received 211 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 51.17% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26251.17% Underperform Votes25048.83% Black Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% Which has preferable valuation and earnings, AKTX or BDTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/ABlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.65 Does the media prefer AKTX or BDTX? In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for Akari Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.76 beat Akari Therapeutics' score of -0.50 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Akari Therapeutics Negative Black Diamond Therapeutics Positive Which has more risk & volatility, AKTX or BDTX? Akari Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500. Do analysts recommend AKTX or BDTX? Black Diamond Therapeutics has a consensus price target of $15.50, indicating a potential upside of 604.55%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of AKTX or BDTX? 5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by company insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryBlack Diamond Therapeutics beats Akari Therapeutics on 8 of the 13 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.90M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.8789.3417.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book-40.176.055.314.79Net Income-$10.01M$154.90M$122.54M$225.00M7 Day Performance-0.41%-0.32%0.59%2.62%1 Month Performance24.23%0.43%2.55%3.81%1 Year Performance-53.65%3.08%25.29%20.10% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$1.21+0.4%N/A-53.7%$31.90MN/A0.009BDTXBlack Diamond Therapeutics2.8567 of 5 stars$2.21+14.5%$15.50+601.4%-20.3%$125.05MN/A-1.6690Positive NewsGap UpHigh Trading VolumeTILInstil Bio2.8084 of 5 stars$18.76-5.5%$114.00+507.7%+119.1%$122.43MN/A-1.62410XBITXBiotech0.6244 of 5 stars$3.99+2.8%N/A-17.8%$121.63M$4.01M-3.69100ALGSAligos Therapeutics4.1379 of 5 stars$33.75+0.1%$75.00+122.2%+101.7%$121.10M$6.00M-2.5390Gap UpTNYATenaya Therapeutics4.0008 of 5 stars$1.51+3.5%$17.33+1,047.5%-63.4%$119.66MN/A-1.05110LPTXLeap Therapeutics1.9275 of 5 stars$3.08+0.7%$7.50+143.5%-20.1%$118.02M$1.50M-1.6040Gap DownATOSAtossa Therapeutics1.3588 of 5 stars$0.92+1.5%$7.00+663.4%+0.7%$115.36MN/A-4.178ANROAlto Neuroscience2.5952 of 5 stars$4.26-2.1%$20.00+369.5%N/A$114.89M$210,000.000.00N/AGap DownIVAInventiva2.6334 of 5 stars$2.17flat$13.25+510.6%-43.6%$113.88M$15.62M0.00100Positive NewsNVCTNuvectis Pharma2.9919 of 5 stars$5.73-1.4%$21.00+266.5%-33.0%$110.71MN/A-4.948Gap Up Related Companies and Tools Related Companies Black Diamond Therapeutics Competitors Instil Bio Competitors XBiotech Competitors Aligos Therapeutics Competitors Tenaya Therapeutics Competitors Leap Therapeutics Competitors Atossa Therapeutics Competitors Alto Neuroscience Competitors Inventiva Competitors Nuvectis Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKTX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
